Last $1.43 USD
Change Today +0.02 / 1.42%
Volume 541.2K
PPHM On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 8:10 PM 11/21/14 All times are local (Market data is delayed by at least 15 minutes).

Financial Statements for peregrine pharmaceuticals (PPHM)

Year over year, Peregrine Pharmaceuticals, Inc. has seen their bottom line shrink from a loss of $29.8M USD to an even larger loss of $35.4M USD despite an increase in revenues from $21.7M USD to $22.4M USD. An increase in the percentage of sales devoted to SGA costs from 60.57% to 77.11% was a key component in the falling bottom line in the face of rising revenues.
Currency in
Millions of US Dollars
As of:Apr 30
2011
Apr 30
2012
Apr 30
2013
Apr 30
2014
4 Year
Trend
Revenues13.515.221.722.4
TOTAL REVENUES13.515.221.722.4
Cost of Goods Sold7.310.212.613.1
GROSS PROFIT6.25.19.19.3
Selling General & Admin Expenses, Total11.411.513.117.3
R&D Expenses29.535.724.327.7
OTHER OPERATING EXPENSES, TOTAL40.947.237.445.0
OPERATING INCOME-34.7-42.1-28.4-35.7
Interest Expense-0.5-0.1-0.10.0
Interest and Investment Income0.10.00.30.3
NET INTEREST EXPENSE-0.40.00.30.3
Other Non-Operating Income (Expenses)1.0------
EBT, EXCLUDING UNUSUAL ITEMS-34.2-42.1-28.1-35.4
Other Unusual Items, Total-----1.7--
Other Unusual Items-----1.7--
EBT, INCLUDING UNUSUAL ITEMS-34.2-42.1-29.8-35.4
Earnings from Continuing Operations-34.2-42.1-29.8-35.4
NET INCOME-34.2-42.1-29.8-35.4
NET INCOME TO COMMON INCLUDING EXTRA ITEMS-34.2-42.1-29.8-35.8
NET INCOME TO COMMON EXCLUDING EXTRA ITEMS-34.2-42.1-29.8-35.8
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PPHM:US $1.43 USD +0.02

PPHM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Argos Therapeutics Inc $8.50 USD -0.41
Dynavax Technologies Corp $14.29 USD -0.22
Inovio Pharmaceuticals Inc $9.98 USD +0.03
Transgene SA €7.83 EUR -0.07
Vical Inc $1.09 USD -0.01
View Industry Companies
 

Industry Analysis

PPHM

Industry Average

Valuation PPHM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 11.0x
Price/Book 3.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 7.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PEREGRINE PHARMACEUTICALS, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.